Skip to content
  • Sunday, 26 July 2026
  • 3:20 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Novel Combination Therapy CagriSema Demonstrates Promising Results in Obesity Management with Preserved Muscle Strength
Pharmaceutical R&D

Novel Combination Therapy CagriSema Demonstrates Promising Results in Obesity Management with Preserved Muscle Strength

Teuku Ryan May 13, 2026 0

On 12 May 2026, at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye, groundbreaking findings from the Phase…

Read More
Pharmaceutical R&D

CagriSema Surpasses Semaglutide in Efficacy and Safety for Obesity and Overweight Management, According to New Meta-Analysis

Teuku Ryan Apr 3, 2026 0

New Orleans, LA – A groundbreaking Bayesian network meta-analysis presented at the American College of Cardiology (ACC) 75th Annual Scientific…

Read More
Laboratory Automation & Robotics

Novo Nordisk’s New Weight Loss Treatment CagriSema Shows Inferiority to Lilly’s Tirzepatide in Head-to-Head Trial

Lana Keisha Apr 3, 2026 0

Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its eagerly anticipated weight loss treatment,…

Read More
Eli Lilly Expands In Vivo Gene Therapy Arsenal with $7 Billion Acquisition of Kelonia TherapeuticsRevolutionary Solar-Powered Desalination Technology Offers a Sustainable Path to Global Clean Water Access and Critical Mineral RecoveryPharma Manufacturing Facility Sales to Outsourcers Signal Growing Industry Demand for Strategic FlexibilityScientists Solve the Two-Century-Old Dolomite Problem by Unlocking the Secret of Pulsed Crystal Growth
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ